ARTICLE | Clinical News
Ruconest conestat alfa regulatory update
March 7, 2016 8:00 AM UTC
EMA’s CHMP recommended expanding the label of Ruconest conestat alfa from Pharming to treat acute angioedema attacks to include adolescents with hereditary angioedema (HAE) due to complement 1 (C1) esterase inhibitor deficiency. The recombinant human C1 esterase inhibitor is approved in adults. ...